Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
biliary tract cancer
fluoropyrimidine
irinotecan
trifluridine/tipiracil
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
03 10 2023
03 10 2023
Historique:
received:
21
12
2022
accepted:
23
04
2023
medline:
4
10
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
We sought to determine the safety and efficacy of trifluridine/tipiracil in combination with irinotecan in a phase II trial setting for refractory, advanced unresectable biliary tract carcinoma (BTC). A total of 28 patients (27 were evaluable) with advanced BTCs who progressed on at least one prior systemic therapy were enrolled and were treated with trifluridine/tipiracil 25 mg/m2 (days 1-5 of 14-day cycle) and irinotecan 180 mg/m2 (day 1 of the 14-day cycle). The primary endpoint for the study was 16-week progression-free survival (PFS16) rate. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety were pre-specified secondary endpoints. Of 27 patients, PFS16 rate was 37% (10/27; 95% CI: 19%-58%), thereby meeting the criteria for success for the primary endpoint. The median PFS and OS of the entire cohort were 3.9 months (95% CI: 2.5-7.4) and 9.1 months (95% CI: 8.0-14.3), respectively. In the patients evaluable for tumor response (n = 20), the ORR and DCR were 10% and 50%, respectively. Twenty patients (74.1%) had at least one grade 3 or worse adverse event (AE), and 4 patients (14.8%) had grade 4 AEs. A total of 37% (n = 10/27) and 51.9% (n = 14/27) experienced dose reductions in trifluridine/tipiracil and irinotecan, respectively. Delay in therapy was noted in 56% of the patients while 1 patient discontinued the therapy, primarily due to hematologic AEs. The combination of trifluridine/tipiracil plus irinotecan is a potential treatment option for patients with advanced, refractory BTCs with good functional status and no targetable mutations. A larger randomized trial is needed to confirm these results. (ClinicalTrials.gov Identifier: NCT04072445).
Sections du résumé
BACKGROUND
We sought to determine the safety and efficacy of trifluridine/tipiracil in combination with irinotecan in a phase II trial setting for refractory, advanced unresectable biliary tract carcinoma (BTC).
METHODS
A total of 28 patients (27 were evaluable) with advanced BTCs who progressed on at least one prior systemic therapy were enrolled and were treated with trifluridine/tipiracil 25 mg/m2 (days 1-5 of 14-day cycle) and irinotecan 180 mg/m2 (day 1 of the 14-day cycle). The primary endpoint for the study was 16-week progression-free survival (PFS16) rate. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety were pre-specified secondary endpoints.
RESULTS
Of 27 patients, PFS16 rate was 37% (10/27; 95% CI: 19%-58%), thereby meeting the criteria for success for the primary endpoint. The median PFS and OS of the entire cohort were 3.9 months (95% CI: 2.5-7.4) and 9.1 months (95% CI: 8.0-14.3), respectively. In the patients evaluable for tumor response (n = 20), the ORR and DCR were 10% and 50%, respectively. Twenty patients (74.1%) had at least one grade 3 or worse adverse event (AE), and 4 patients (14.8%) had grade 4 AEs. A total of 37% (n = 10/27) and 51.9% (n = 14/27) experienced dose reductions in trifluridine/tipiracil and irinotecan, respectively. Delay in therapy was noted in 56% of the patients while 1 patient discontinued the therapy, primarily due to hematologic AEs.
CONCLUSION
The combination of trifluridine/tipiracil plus irinotecan is a potential treatment option for patients with advanced, refractory BTCs with good functional status and no targetable mutations. A larger randomized trial is needed to confirm these results. (ClinicalTrials.gov Identifier: NCT04072445).
Identifiants
pubmed: 37339254
pii: 7204081
doi: 10.1093/oncolo/oyad144
pmc: PMC10546810
doi:
Substances chimiques
Irinotecan
7673326042
tipiracil
NGO10K751P
Trifluridine
RMW9V5RW38
Banques de données
ClinicalTrials.gov
['NCT04072445']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
917-e966Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Br J Cancer. 2018 Aug;119(3):291-295
pubmed: 29955136
Anticancer Res. 2015 Mar;35(3):1437-45
pubmed: 25750295
Am J Clin Oncol. 2000 Aug;23(4):425-8
pubmed: 10955877
Br J Cancer. 2017 Feb 28;116(5):561-567
pubmed: 28081540
Int J Oncol. 2004 Sep;25(3):571-8
pubmed: 15289858
Cancer Treat Rev. 2015 Nov;41(9):777-83
pubmed: 26428513
Tumori. 2014 Mar-Apr;100(2):219-24
pubmed: 24852869
Ann Oncol. 2001 Apr;12(4):501-4
pubmed: 11398883
Br J Cancer. 2004 Nov 15;91(10):1769-74
pubmed: 15505626
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
J Gastrointest Oncol. 2014 Dec;5(6):408-13
pubmed: 25436118
Control Clin Trials. 1989 Mar;10(1):1-10
pubmed: 2702835
Oncologist. 2020 May;25(5):380-e763
pubmed: 31826977
Pharmacol Ther. 2021 Aug;224:107823
pubmed: 33667525
Int J Oncol. 2000 Aug;17(2):277-83
pubmed: 10891536
Ann Oncol. 2014 Dec;25(12):2328-2338
pubmed: 24769639
Mol Clin Oncol. 2022 Feb;16(2):52
pubmed: 35070301
Lancet Oncol. 2021 May;22(5):690-701
pubmed: 33798493